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Purpose: To determine the incidence and clinical features of incidentally discovered prostate adeno-
carcinoma in patients undergoing radical cystoprostatectomy (CPT) for bladder cancer.
Methods: Ninety-six consecutive patients scheduled to undergo CPT were prospectively enrolled. The
prostates were excised completely during CPT. The CPT specimens were examined, and the clinico-
pathologic characteristics of incidental prostate cancer studied. Complete transverse sections of the
prostate were taken from the apex to the base at 4-mm intervals and all prostates were examined by a
single pathologist.
Results: The mean patient age and prostate-speciﬁc antigen level were 66.1 ± 10.0 years and
2.8 ± 5.0 ng/mL, respectively. Of the 96 patients, 35 (36.5%) had prostate cancer (PCa). Of these incidental
PCas, 57.1% (20.8% of all patients undergoing CPT) were clinically signiﬁcant. None of the patients who
were age 50 years had incidental PCa. However, the incidences of PCa in the 51e60 years, 61e70 years,
and 71 years age groups were 27.8% (5/18), 48.7% (19/39), and 35.5% (15/31), respectively, and the
difference according to the age subgroup was signiﬁcant (P ¼ 0.048). During the median follow-up of 49
months, 29.2% (28/96) of patients died. There were no PCa-speciﬁc deaths, and two patients (2.1%)
showed biochemical recurrences.
Conclusion: Incidental PCas were diagnosed in ~40% of CPT specimens, and ~50% of incidental PCas were
clinically signiﬁcant. During radical CPT in patients aged 60 years, the possibility of the presence of PCa
and the potential oncologic risk of partial prostatectomy during CPT should be remembered.
© 2015 Published by Elsevier B.V. on behalf of Prostate International. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer (PCa) is the most frequently diagnosed malig-
nancy and the second leading cause of cancer-specific deaths in
men in Western industrialized countries. In 2012, about 241,740
men were estimated to have been diagnosed with PCa in the USA.1
Although the incidence of PCa is lower in Korea compared to the
USA, it has been increasing in recent years. According to 2010
Cancer Statistics in Korea, prostate is among the ﬁve leading pri-
mary cancer sites in men, and the mortality rates of PCa have also
increased.2National Cancer Center, 323
orea.
ier B.V. on behalf of Prostate InteThe prevalence of PCa far exceeds that of clinically detected
disease. In autopsy studies, the prevalence of silent PCa varies
among different ethnic and age-related groups. The majority of
incidental prostate tumors is small, organ-conﬁned, and considered
clinically insigniﬁcant. Many of these tumors will never present
with clinical signs during the lifetime of these men.3 Radical cys-
toprostatectomy (CPT) specimens represent a random sample of
prostates from asymptomatic men, and these samples are then
subjected to pathological examination and the patients undergo a
clinical follow-up. This cohort is similar to that in autopsy studies in
terms of randomness. Autopsy studies have revealed that PCas are
found incidentally in 30% of 50-year-old men, and in 70% of 80-
year-old men in the USA.4 Compared with Western countries,
fewer studies on incidental PCa have been conducted in Asian
countries. Clinical data in Asian countries are sparse because most
of the published studies have been performed retrospectively. Wernational. This is an open access article under the CC BY-NC-ND license (http://
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Korean men about 5 years ago. It was the ﬁrst prospectively per-
formed study. However, the limitation of that study was the small
sample size and short-term follow-up.5 Therefore, we performed a
larger cohort study with a longer observation period. Our aim was
to review the features of incidentally discovered prostate adeno-
carcinoma in patients with bladder cancer with regard to its inci-
dence, pathologic characteristics, and clinical signiﬁcance.
2. Methods
2.1. Study population
The study protocol was approved by the Institutional Review
Board of the Korean National Cancer Center, Goyang, Korea. One
hundred consecutive male patients who were scheduled to un-
dergo CPT and had no history or clinical evidence of PCa before
surgery were enrolled into this study between January 2005 and
December 2012 at a single institution. Routine preoperative
evaluations included abdominal computed tomography, bone
scans, digital rectal examination, and serum prostate-speciﬁc
antigen (PSA) assay. Standard CPT with bilateral pelvic lympha-
denectomy was performed in patients with transitional cell car-
cinoma (TCC) of the bladder. Four patients who underwent pelvic
exenteration including CPT for other concomitant malignancies
were excluded. Finally, this study was performed in a total of 96
Korean patients with TCC of the bladder or prostatic urethra. For
urinary diversion, ileal conduit and orthotopic ileal bladder
substitution were performed in 72 (75.0%) and 22 (22.9%) pa-
tients, respectively. In two patients (2.1%), partial cystectomy and
radical prostatectomy was performed for TCC of the bladder neck
or prostatic urethra. After CPT, regular computed tomography
scans were performed during follow-up to detect primary tumor
recurrence. Patients with incidental PCa were also scheduled for
digital rectal examination and serum PSA evaluation at every 3
months for the 1st postoperative year and biannually thereafter.
Biochemical recurrence was deﬁned as a sustained PSA level
>0.4 ng/mL on two or more consecutive occasions. Patients were
evaluated according to age, tumor focality, tumor location,
Gleason score, pathological tumor stage, extracapsular extension,
seminal vesicle invasion, surgical margin status, tumor volume,
and clinical signiﬁcance. Follow-up data included data for adju-
vant treatment, tumor relapse, subsequent medical intervention,
and survival status.
2.2. Histopathologic evaluations
CPT specimens were immersed intact in formalin solution. The
prostate and seminal vesicles were removed en bloc from the
bladder, and the entire circumference of each resected prostate
gland was inked. Complete transverse sections were taken from the
apex to the base at 4-mm intervals. All prostates were examined by
a single pathologist (W.S.P.). When adenocarcinoma of the prostate
was detected, tumor location and tumor volume were noted
{deﬁned as [0.4(slope of the regression line) lengthwidth CPT
thickness (number of cross sections  sectional thickness)]}.6
Gleason score, presence of extracapsular extension, and evidence
of seminal vesicle invasion were assessed. The 2002 Tumor-Node-
Metastasis (TNM) classiﬁcation was used to determine the patho-
logic stage, and if needed, immunohistochemical staining was per-
formed using speciﬁc antibodies against PSA, prostate-speciﬁc
membrane antigen, prostate stem cell antigen, a-methylacyl-coen-
zyme racemase, or p63. Signiﬁcant PCa was deﬁned as a tumor
volume of 0.5 cm3 or larger, a Gleason score 7, presence of
extraprostatic extension, or a positive surgical margin.72.3. End points and statistical analyses
In the present study, we determined the prevalence of PCa in
CPT specimens and evaluated whether these cancers were clinically
signiﬁcant. Then, we studied the clinical characteristics of these
patients and determined the relationships between clinical pa-
rameters including age, PSA, and pathologic information. Chi-
square analysis (or Fisher's exact test for nonparametric variables)
was used to analyze categorical variables and the t test (or Man-
neWhitney U test for nonparametric variables) was used to analyze
continuous variables. SPSS for Windows, version 12.0 (SPSS Inc.,
Chicago, IL, USA) was used for all statistical analyses, and two-sided
P < 0.05 were considered signiﬁcant.
3. Results
3.1. Patient characteristics
The clinicopathological characteristics of 96 men are sum-
marized in Table 1. Radical CPT with ileal conduit diversion was
performed in 72 patients (75.0%), CPT with ileal neobladder
substitution in 22 (22.9%), and partial cystectomy and prosta-
tectomy in two patients (2.1%). The mean age and preoperative
PSA level of the patients were 66.1 ± 10.0 years and 2.8 ± 5.0 ng/
mL. Thirty-nine patients (40.6%) had incidental PCa that was
diagnosed after surgery. Of these 39 patients, clinically signiﬁ-
cant PCa was found in 57.1% (20.8% of all CPT patients; Table 2).
The mean age in the 35 patients with incidental PCa was
69.1 ± 8.4 years and in patients without incidental prostate
cancer was 64.4 ± 10.5 years, and this difference was signiﬁcant
(P ¼ 0.025). Mean serum PSA level in patients with incidental PCa
was signiﬁcantly higher than that in patients without incidental
prostate cancer (4.6 ± 7.3 ng/mL and 1.7 ± 2.2 ng/mL, respec-
tively, P ¼ 0.013). The incidence of PCa among eight patients who
were aged 50 years was zero. However, the incidences of PCa in
patients in the 51e60 years, 61e70 years, and 71 years age
groups were 27.8% (5/18), 48.7% (19/39), and 35.5% (15/31),
respectively, and the difference according to the age subgroup
was signiﬁcant (P ¼ 0.048; Table 1). The incidences of clinically
signiﬁcant PCa in patients in the 51e60 years, 61e70 years, and
71 years age groups were 11.1% (2/18), 25.6% (10/39), and 25.8%
(8/31), respectively, and the difference according to the age
subgroup was insigniﬁcant (Table 2). As an adjuvant therapy, 39
patients with bladder TCC received platinum-based combination
chemotherapy (e.g., methotrexate, vinblastine, actinomycin, and
cisplatin or gemcitabine and cisplatin regimens), and one patient
with PCa and lymph node metastasis underwent androgen
ablation therapy with gonadotropin-releasing hormone agonists
and antiandrogens.
3.2. Histopathologic characteristics
Among all of the patients, 35 (36.5%) had incidental PCa. Among
them, high-grade prostatic intraepithelial neoplasia (HGPIN) was
detected in 60.0% of patients (21.9% of all CPT patients). Twenty
patients (20.8% of all patients) had an HGPIN without adenocarci-
noma (data are not shown). The histopathological characteristics
are summarized in Table 3. According to the pathologic staging of
incidental PCas, 21 cases (60.0%) were classiﬁed as pT2a, seven
cases (20.0%) as pT2b, ﬁve cases (14.3%) as pT2c, one case (2.9%) as
pT3b, and one case (2.9%) as pT4N1M0. Gleason scores ranged from
2 to 4 in four cases (10.2%), from 5 to 6 in 31 cases (79.5%), and from
7 to 10 in four cases (10.2%). Gleason scores from 2 to 4 of pathology
were not deﬁned as prostate cancer. Mean tumor volume was
0.9 ± 0.9 cm3, and a tumor volume >0.5 cm3 was identiﬁed in 22
Table 1
The clinical characteristics of patients who underwent cystoprostatectomy according to the presence of incidental prostate cancer (PCa; n ¼ 96).
Variable Total patients Patients without incidental PCa Patients with incidental PCa P
Patients 96 (100.0) 61 (63.5) 35 (36.5) e
Age (y) 66.1 ± 10.0 64.4 ± 10.5 69.1 ± 8.4 0.025
PSA level (ng/mL) 2.8 ± 5.0 1.7 ± 2.2 4.6 ± 7.3 0.013
Age subgroup (y)
 50 8 (100.0) 8 (100.0) 0 (0.0) 0.048
51e60 18 (100.0) 13 (72.2) 5 (27.8)
61e70 39 (100.0) 20 (51.3) 19 (48.7)
 71 31 (100.0) 20 (64.5) 15 (35.5)
Data are presented as n (%) or mean ± SD.
PSA, prostate-speciﬁc antigen.
Table 2
The clinical characteristics of patients who underwent cystoprostatectomy according to the presence of clinically signiﬁcant prostate cancer (PCa; n ¼ 96).
Variable Total patients Patients without signiﬁcant PCa Patients with signiﬁcant PCa P
Patients 96 (100.0) 76 (79.2) 20 (20.8) e
Age (y) 66.2 ± 10.1 64.8 ± 10.0 71.4 ± 8.8 0.008
PSA level (ng/mL) 2.9 ± 5.0 1.9 ± 2.3 6.3 ± 9.1 0.001
Age subgroup (y)
 50 8 (0.0) 8 (100.0) 0 (0.0) 0.290
51e60 18 (100.0) 16 (88.9) 2 (11.1)
61e70 39 (100.0) 29 (74.4) 10 (25.6)
 71 31 (100.0) 23 (74.2) 8 (25.8)
Data are presented as n (%) or mean ± SD.
PSA, prostate-speciﬁc antigen.
Table 3
Histopathologic characteristics of incidental prostate cancer according to age subgroup (n ¼ 35).
Variable Total patients Age subgroup (y) P
51e60 61e70  71
Patients 35 (100.0) 5 (14.3) 19 (54.3) 11 (31.4) e
PSA level (ng/mL) 4.4 ± 6.9 3.1 ± 4.2 4.6 ± 8.3 4.4 ± 5.7 0.942
Pathologic stage
Prostate conﬁned 33 (100.0) 5 (15.2) 19 (57.6) 9 (27.3) 0.361
Extraprostatic extension 1 (100.0) 0 (0.0) 0 (0.0) 1 (100.0)
Lymph node metastasis 1 (100.0) 0 (0.0) 0 (0.0) 1 (100.0)
Gleason score
5e6 31 (100.0) 4 (12.9) 17 (54.8) 10 (32.3) 0.796
7e10 4 (100.0) 1 (25.0) 2 (50.0) 1 (25.0)
Tumor volume (cm3) 0.9 ± 0.9 0.4 ± 0.2 0.9 ± 0.7 1.1 ± 1.1 0.238
Tumor volume
>0.5 cm3 22 (100.0) 2 (9.1) 11 (50.0) 9 (40.9) 0.236
0.5 cm3 13 (100.0) 3 (23.1) 8 (61.5) 2 (15.4)
Multiplicity
Present 10 (100.0) 1 (10.0) 4 (40.0) 5 (50.0) 0.316
Absent 24 (100.0) 3 (10.7) 15 (53.6) 6 (25.0)
Apex involvement
Present 5 (100.0) 1 (20.0) 3 (60.0) 1 (20.0) 1.000
Absent 30 (100.0) 4 (13.3) 16 (53.3) 10 (33.3)
Margin status
Positive 3 (100.0) 0 (0.0) 3 (100.0) 0 (0.0) 0.722
Negative 29 (100.0) 5 (17.2) 15 (51.7) 9 (31.0)
Data are presented as n (%) or mean ± SD.
BC, bladder cancer; CI, conﬁdence interval; Cis, carcinoma in situ; HR, hazard ratio; LA, locally advanced; PSA, prostate-speciﬁc antigen; PSCA, prostate stem cell antigen.
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found in ﬁve of the 35 patients (14.3%). Three of the 32 patients
(9.4%) had a positive surgical margin. Histopathologic characteris-
tics of incidental PCa between age subgroups showed no signiﬁcant
differences.
3.3. Follow-up
Follow-up data were available for all of the 96 patients who
underwent CPT. Median follow-up period was 49.0 months afterCPT (range, 10.0e90.0 months). Twenty-eight deaths had occurred
by the time of analysis; 26 patients died of bladder cancer pro-
gression; and two patients died of other conditions. However, there
were no PCa-speciﬁc deaths. The KaplaneMeier survival curve
showed that the presence of PCa (signiﬁcant or not) was not
associated with risk of mortality after CPT (Fig. 1). Except for one
patient, almost all of the patients (30/31, 96.8%) with incidental PCa
had undetectable serum PSA levels at 3 months after CPT. During
the follow-up period, two of the 30 patients experienced a
biochemical recurrence.
Fig. 1. Overall survival of patients. Patients (A) with or without incidental prostate cancer and (B) with or without clinically signiﬁcant prostate cancer (PCa) in the cys-
toprostatectomy specimens. CPT, cystoprostatectomy.
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Several studies have reported incidental PCa detection rates of
14e60% in CPT specimens (Table 4).5 These high detection rates
may be related to hereditary and exogenous factors, such as food
consumption and patterns of sexual behavior. These substantial
differences between studies can also be probably explained by the
different pathologic evaluation methods used and different patient
characteristics. The detailed pathological examination of the
excised prostatic tissue specimensmay be another important factor
for the detection of small cancer.8 In this respect, two important
issues are the thickness of the slice of the prostate and whether the
prostate is totally embedded.9 The advantage of complete sampling
over partial sampling is that small foci of cancer are seen more
frequently. When prostate slices are thicker than 5 mm, small foci
of cancer within the slice might be missed. By complete sampling,
cancer features, such as extraprostatic extrusion and positive
margins, are more accurately evaluated.10 Some investigators have
suggested that the prostatic apex should be preserved to improve
the results of continent neobladder substitution.11 According to our
literature search, the highest prevalence was reported by Winkler
et al.,12 who reported a rate of 60%, and the lowest prevalence of
only 14% was reported by Delongchamps et al.13 Among Asian
studies, a Taiwanese study reported that only 4% of 248 CPT cases
had incidental PCa using a 5-mm section interval.14 By contrast, inTable 4
Published reports on incidental prostate cancer (PCa) in radical cystectomy specimens.
Study Years Country n Mean age (y) Section (mm) P
n
Pritchett24 1988 USA 165 NA NA 4
Abbas25 1996 USA 40 64.3 2e3 1
Revelo et al.7 2004 USA 121 67.4 2e3.5 5
Delongchamps et al.13 2005 France 141 62 4 2
Abdelhady et al.3 2006 Canada 204 67 NA 5
Winkler et al.12 2007 UK 97 NA 2 5
Joung et al.5 2008 Korea 36 66 4 1
Nakagawa et al.15 2009 Japan 349 65 5 9
Gakis26 2010 Germany 95 68 4e5 2
Aytac27 2011 Turkey 300 62 3e5 6
Alsinnawi28 2012 Ireland 110 66 4 3
Present study 2013 Korea 96 66 4 3
G, Gleason score.
Data underlined indicate those spread across different gleason scores.our previous report, PCa was detected in 18 of 36 patients (50%)
who had undergone CPT when prostates were transversely
sectioned at 4-mm intervals from the apex to the base.5 Another
Asian study by Nakagawa et al.15 demonstrated a prevalence of 27%
for incidental PCa among 349 patients, using a 5-mm section. In our
present study (n ¼ 96), incidental PCa was detected in 36.5% of all
the men. Furthermore, HGPIN, a precursor lesion of prostatic
adenocarcinoma, has a prevalence ranging from 0.7% to 16.5% in the
West according to reports from various institutions. In the present
study, HGPIN was found in 60% of PCa patients (21.9% of all CPT
patients). Speciﬁcally, isolated HGPIN was found in 20 CPT speci-
mens (20.8%) without evidence of PCa, which is a higher prevalence
rate than that reported previously in studies on isolated HGPIN.16,17
Twomajor determinants of the PCa detection rate in CPT specimens
are the sampled populations in terms of age and ethnicity, and the
histopathological work-up of the specimens in terms of the pro-
portion of tissue analyzed (whole mount vs. partial mount) and the
width of sections. Mean patient age was the highest in our study
than in other Asian studies, and detailed pathologic examinations
were performed in our study (4-mm whole-mount step sections)
than in other Asian studies (5-mm whole mount step section:
Taiwanese study, 5-mm section with an unknown sampling tech-
nique: Japanese study).
Our updated data showed a prevalence of 36.5% for incidental
PCa in 96 CPT cases after sectioning at 4-mm intervals, but 42.8% ofCa
(%)
Signiﬁcant PCa, n (%) G2e4
%
G5
%
G6
%
G7
%
G8e10
%
pT2
%
pT3
%
5 (27) NA e e e e e 82 18
8 (45) NA 28 67 67 67 5 67 33
0 (41) 24 (48) 80 80 80 16 4 84 16
0 (14.2) 14 (70) 90 90 90 10 0 90 10
8 (28.4) 18 (31) 78 78 78 20 2 90 10
8 (60) 31 (53) e e e e e e e
8 (50) 7 (39) 17 67 67 17 17 94.4 5.6
1 (26.1) 68 (74.7) 26 26 26 69 4 93.4 6.6
6 (27) 7 (27) 85 85 85 15 0 100 0
0 (20) 40 (66.6) 80 80 80 20 0 90 10
5 (32.5) 10 (28.5) 80 80 80 14 6 94 6
9 (40.6) 20 (51.3) 10 79 79 10 10 94.9 5.1
I.-C. Cho et al. / Prostate International 3 (2015) 56e6160incidental PCa cases were considered clinically insigniﬁcant (tumor
volume  0.5 cm3, and Gleason score < 7). These results are com-
parable with the data presented in many Western studies .7,12
However, the largest Asian study by Nakagawa et al.15 demon-
strated a low prevalence of incidental PCa (26.1%) and a high
prevalence of clinically signiﬁcant PCa (74.7%). These ﬁndings
provide strong evidence that the reported prevalence of PCa in the
CPT specimens is related to the section size. Signiﬁcant PCa was
relatively broadly deﬁned in the Japanese study than in our study.
In addition, racial heterogeneity might have also existed.
In several autopsy studies, the prevalence of silent PCa varies
among different ethnic and age-related groups. In autopsy studies,
the prevalence of PCa also varies according to the country. The
prevalence of incidental PCa is estimated to be 14e70 % in the 7th
decade, and the highest prevalence rate is seen in African Ameri-
cans.18 The incidence rate of PCa in our study (36.5%) is similar to
that in the Japanese (32%) and Hungarian (44%) autopsy studies.18
The prevalence of incidental PCa in this study is much higher
than that in the autopsy study conducted in China, which reported
a prevalence of incidental PCa of 9.3% in men aged 51e69 years and
a prevalence of 25% in men aged 70 years.19 There is some pre-
liminary molecular evidence suggesting that the association be-
tween TCC and PCamight arise from a congruence in the expression
of tumor suppressor genes (p53 and pRb) in both bladder and
prostate cancers.20 However, these datawere obtained from a small
sample of patients presenting with both malignancies (n ¼ 15).20
An autopsy study on PCa in age-matched Korean men without
bladder cancer is required to assess the additional risk of PCa in
men who have bladder cancer. In this study, we showed an inci-
dence of 36.5% for incidental PCa in CPT specimens from the largest
cohort of patients undergoing radical CPT in Korea. Our data indi-
cated that the prevalence of PCa in the specimens increased ac-
cording to age after CPT for bladder cancer. We found that the
detection rate of PCa was signiﬁcantly higher in the 61 years
group (48.5%) than in the age  60 years group (19.2%). Pettus
et al.21 demonstrated a signiﬁcant association between age and
concomitant PCa in 235 CPT specimens with a multivariable odds
ratio of 1.3 (conﬁdence interval 1.0e1.8; P ¼ 0.046) per 10 years
increase in age. In addition, Buse et al.22 quantiﬁed the increase in
the odds ratio of PCa at 2.8% per year in these patients. In our
cohort, we also found a signiﬁcant association between age and the
prevalence of occult PCa in the CPT specimens; however, we could
not quantify the strength of the association due to the small sample
size.
Histological criteria have been developed based on CPT speci-
mens regarding differences between clinically signiﬁcant versus
insigniﬁcant PCa.23 Clinically signiﬁcant cancers are deﬁned as
having a volume >0.5 mL or a Gleason grade >6, or are locally
invasive. Tumors that do not meet any of these criteria are thought
to represent clinically insigniﬁcant, low biological risk tumors that
are unlikely to cause risk to the health of the patient. In our study,
the prevalence of PCa increased with age. Overall 57.1% (20 of 35) of
the tumors were clinically signiﬁcant according to the histological
deﬁnition, but two of all the tumors in men younger than 60 years
(40%, 2 of 5) were clinically signiﬁcant. In addition, there was no
correlation between age and prevalence of signiﬁcant PCa. This may
be due to the small sample size of our study.
During the median follow-up period of 40 months after CPT,
29.2% (28/96) of patients died. Survival data showed no additional
risk according to the presence of PCa. There were no PCa-speciﬁc
deaths and two patients (2.1%) showed biochemical recurrences,
which suggests that the outcome of patients with incidental PCa
after CPT depends on the prognosis of the primary tumor. By
contrast, in their large cohort study, Buse et al.22 concluded that
concomitant PCa is an independent prognostic factor for mortalityafter radical CPT for bladder cancer. However, the follow-up period
in our study was longer (median, 40 months), and we routinely
performed complete excision of the prostate gland during CPT at
our institution unlike in the study by Buse et al.22 These differences
could have affected the results.
A number of factors may have contributed to the variation be-
tween the ﬁndings of the current study and earlier studies. First, in
the current study, unlike in earlier studies, a relatively homoge-
neous group of patients was assessed. The study population
comprised of native Koreans. Second, this was a prospective, well-
designed study with consistency in histopathological work-up of
the specimens in terms of the proportion of tissue analyzed and the
width of the sections. Third, the follow-up period of this study was
the longest among the studies published in the literature to date.
Our present study has some limitations that need to be mentioned.
It is limited by a small sample size. A larger cohort study is required
to determine the overall outcome of Korean patients with inci-
dental PCa. In addition, CPT specimens represent a random sample
of prostates from asymptomatic men, which are then subjected to
pathological examination and to clinical follow-up. This cohort is
similar to autopsy studies in terms of randomness, but differs
fundamentally.
In conclusion, incidental PCas were detected in 36% of CPT
specimens, with about half of the specimens showing characteris-
tics of clinically signiﬁcant PCa. Increasing patient age is associated
with a high incidence of incidental PCa. During radical CPT in pa-
tients aged60 years, the possibility of the presence of PCa and the
potential oncologic risk of partial prostatectomy during CPT should
be remembered.
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